期刊文献+

肝细胞癌四种临床分期系统预后判断和治疗指导价值的比较 被引量:5

Comparison of four staging systems in predicting outcomes and guiding option of treatment for patients with hepatocellular carcinoma
原文传递
导出
摘要 目的 比较4个分期系统[巴塞罗那临床肝癌分期标准(BCLC)、日本综合分期积分(JIS)、意大利肝癌评分(CLIP)和国内分期]对中国肝癌患者预后判断和对治疗方案选择的指导意义.方法 回顾性分析2001年至2002年复旦大学附属中山医院收治的861例初发肝细胞癌患者的临床资料,分别按4个分期系统分期或评分,比较各期患者的生存情况以及不同治疗方案对其生存的影响.结果 在判断预后方面,BCLC、JIS和国内分期系统的各分期间生存率差异均有统计学意义;而在CLIP分期的一些评分间的生存率差异无统计学意义.在指导治疗方面,BCLC C期,CLIP 3、4分以及国内分期ⅢA期的患者接受手术治疗与接受肝动脉化学治疗栓塞(TACE)和(或)肝动脉栓塞(TAE)治疗的生存率差异无统计学意义;而比这些更早期的患者接受手术治疗的生存率优于接受TACE和(或)TAE治疗的生存率.结论 BCLC、JIS和国内分期系统在判断预后方面适用于中国患者;但仅国内分期和BCLC分期同时兼备了判断预后和指导治疗两方面的作用. Objective To compare the Barcelona clinic liver cancer staging classification (BCLC), the Japan integrated staging score (JIS), the cancer of the liver Italian program score (CLIP) and Chinese staging system in terms of their ability to predict outcomes and to guide option of therapy in patients with hepatocellular carcinoma (HCC) in China.Methods Clinical data of 861 HCC patients from Zhongshan Hospital between 2001 and 2002 were retrospectively analyzed. Patients were classified acccording to different staging systems. Survival for patients in different stages and the effects of therapeutic methods on survival time were compared. Results BCLC, JIS and Chinese staging system showed the ability in predicting survival for patients in different staging. CLIP failed to show significant difference in survival rates for each subgroup. There was no significant difference in survival rate between surgery and transarterial chemoembolization (TACE)/transarterial embolization (TAE) for patients classified as BCLC stage C, CLIP scores more than 3 or Chinese stage Ⅲ a.The survival rate, however, was higher in patients received operation than those received TACE/TAE if they were classified as earlier stages. Conclusions The BCLC, JIS and Chinese staging systems show prospective ability for Chinese HCC patients in prediction outcomes, whereas the BCLC and the Chinese staging systems are better at both predicting outcomes and guiding the option of treatment.
出处 《中华消化杂志》 CAS CSCD 北大核心 2010年第6期374-377,共4页 Chinese Journal of Digestion
关键词 肝细胞癌 分期系统 判断预后 指导治疗 Hepatocellular carcinoma Staging systems Prognostic ability Therapeutic guiding ability
  • 相关文献

参考文献8

  • 1Llovet JM,Brú C,Bruix j.Prognosis of hepatocellular carcinoma:the BCLC staging classification.Semin Liver Dis,1999,19:329-338. 被引量:1
  • 2Leung TW,Tang AM,Zee B,et al.Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system,the Okuda staging system,and the Cancer of the Liver Italian Program staging system:a study based on 926 patients.Cancer,2002,94:1760-1769. 被引量:1
  • 3Marrero JA,Fontana RJ,Barrat A,et al.Prognosis of hepatocellular carcinoma:comparison of 7 staging systems in an American cohort.Hepatology,2005,41:707-716. 被引量:1
  • 4Cillo U,Bassanello M,Vitale A,et al.The critical issue of hepatocellular carcinoma prognostic classification:which is the best tool available? J Hepatol,2004,40:124-131. 被引量:1
  • 5Cammà C,Di Marco V,Cabibbo G,et al.Survival of patients with hepatocellular carcinoma in cirrhosis:a comparison of BCLC,CLIP and GRETCH staging systems.Aliment Pharmacol Ther,2008,28:62-75. 被引量:1
  • 6杨秉辉,夏景林.原发性肝癌的临床诊断与分期标准[J].中华肝脏病杂志,2001,9(6):324-324. 被引量:1015
  • 7Fibrinogen Studies Collaboration.Measures to assess the prognostic ability of the stratified Cox proportional hazards model.Stat Med,2009,28:389-411. 被引量:1
  • 8Llovet JM,Bruix j.Molecular targeted therapies in hepatocellular carcinoma.Hepatology,2008,48:1312-1327. 被引量:1

共引文献1014

同被引文献52

引证文献5

二级引证文献36

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部